{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.12","value":"-1.24"},{"groupId":"OG001","spread":"5.7","value":"-0.24"},{"groupId":"OG002","spread":"9.719","value":"-6.07"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"34"}],"units":"Participants"}],"description":"Seizure frequency per 24 hours was defined as the number of seizures in the electroencephalography (EEG) divided by the number of hours in the EEG, multiplied by 24. Seizure frequency was evaluated using a 24-hour video-EEG. Seizure frequency was listed as missing if the actual EEG recording duration was \\< 18 hours.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received oral dose of everolimus 4.5 mg/m\\^2 daily as an initial starting dose to attain the whole blood trough concentrations in range of 5-15 ng/mL. Dose adjustments were permitted based on safety and whole blood trough concentrations.","id":"OG000","title":"Everolimus (Core Period)"},{"description":"Participants received oral dose of placebo matching to everolimus daily.","id":"OG001","title":"Placebo (Core Period)"},{"description":"Participants received oral dose of everolimus 4.5 mg/m\\^2 daily as an initial starting dose to attain blood trough concentrations in range of 5-15 ng/mL.","id":"OG002","title":"Everolimus (Extension Period)"}],"paramType":"MEAN","populationDescription":"The analysis was performed in the FAS population. Missing values were imputed using last observation carried forward approach for core period while raw count for extension period.","reportingStatus":"POSTED","timeFrame":"Baseline (Core period) to Week 24 (Core period), Baseline (Extension period, Week 24 post-core baseline) to Week 24 (Extension period, Week 48 post-core baseline)","title":"Change From Baseline in Frequency of Total Seizure Events Per 24 Hours at Week 24 in Both Core and Extension Period","type":"SECONDARY","unitOfMeasure":"Seizure frequency"}